CWM
RARE icon

Catamount Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Catamount Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-30
Closed -$2K – 198
2017
Q2 		$2K Buy
+30
New +$1.81K ﹤0.01% 161

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Catamount Wealth Management's RARE Position: Q3 2017 in Review

Catamount Wealth Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2017, closing a stake of 30 shares — an estimated $2K sold.

Catamount Wealth Management first reported a position in RARE in Q2 2017 and held it in 1 quarter. The position peaked at $2K in Q2 2017. 154 funds tracked by Wall St. Rank hold RARE as of Q3 2017.

  • Catamount Wealth Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2017 after selling out during the quarter.
  • Catamount Wealth Management sold 30 Ultragenyx Pharmaceutical shares in Q3 2017, an estimated $2K.
  • Catamount Wealth Management first reported a position in Ultragenyx Pharmaceutical in Q2 2017 and held it in 1 quarter.
  • Catamount Wealth Management's Ultragenyx Pharmaceutical position peaked at $2K in Q2 2017.
  • 154 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2017.

Based on Catamount Wealth Management's 13F filing for Q3 2017, filed 13 Nov 2017.